Latest Tax Incentives News

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Memphasys Limited has disclosed a $1.118 million liability linked to its FY24 R&D tax rebate following an ASX inquiry, while confirming compliance with continuous disclosure rules and ongoing engagement with the ATO for a private ruling.

FortifAI Limited reported steady revenue and significant cost reductions in Q1 FY26, while securing new contracts and advancing AI initiatives to boost operational efficiency.

Hazer Group has received a $4.58 million R&D tax incentive refund for FY25, reinforcing its financial position as it advances its methane pyrolysis technology towards commercialisation.

Great Dirt Resources reports promising lithium soil anomalies in Western Australia's Pilbara region and progresses manganese exploration in New South Wales, supported by a solid cash position of $2.4 million.

Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.

333D Ltd reports a fifth consecutive quarter of revenue growth, secures $1 million in fresh capital, and expands its blockchain healthcare initiatives while building a strategic Bitcoin treasury.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

FBR Limited’s 2025 Annual Report reveals a substantial $54 million impairment charge that significantly worsens its financial results, pushing total losses to nearly $83 million. The adjustments highlight challenges in capitalised development and asset valuations amid ongoing robotics innovation.